| Document |
Document Title |
|
WO/2002/038579A1 |
Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.
|
|
WO/2002/038578A1 |
The present invention relates to modified nucleotides and nucleosides and reagents to produce these. The modified nucleotides and nucleotides are assembled to larger oligonucleotides and oligonucleosides, which, for example, may be used ...
|
|
WO2001068034B1 |
Prodrug forms of Levovirin include bio-reversible modifications on the sugar moiety and/or bio-reversible modifications on the triazole moiety. Contemplated prodrug forms may be used in pharmaceutical compositions, which may be used to t...
|
|
WO/2002/036601A2 |
The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of can...
|
|
WO/2002/036832A2 |
Substantially pure atropisomers of xanthene compounds are disclosed. A variety of molecular biology applications utilize atropisomeric xanthene fluorescent dyes as labels for substrates such as nucleotides, nucleosides, polynucleotides, ...
|
|
WO/2002/032920A2 |
The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal...
|
|
WO/2002/032912A2 |
Phosphinoamidite carboxylates and analogs are provided that have the structure of formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, X, Y, Z and n are as defined herein. The compounds are useful as phosphitylating agents, e.g., in the phosp...
|
|
WO/2002/033128A2 |
Processes and methods for the simultaneous quantification of nucleic acids in protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral...
|
|
WO/2002/030944A2 |
Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are ...
|
|
WO/2002/030941A2 |
The present invention relates to novel N12, N13-bridged sugar derivatives of indolylopyrrolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor...
|
|
WO/2002/030942A2 |
The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
|
|
WO/2002/030354A2 |
The invention is based on the discovery that patients having elevated purine levels, e.g., individuals diagnosed with pervasive developmental disorders, such as autistic disorder, and/or neuromuscular disorders, can be treated with uridi...
|
|
WO/2002/029003A2 |
This invention provides methods for attaching a nucleic acid to a solid surface and for sequencing nucleic acid by detecting the identity of each nucleotide analogue after the nucleotide analogue is incorporated into a growing strand of ...
|
|
WO/2002/028874A2 |
The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
|
|
WO/2002/028875A2 |
The present invention relates to a new method for the synthesis of purine LNA (Locked Nucleic Acid) analogues which provides a higher overall yield. The method comprising a regioselective 9-N purine glycosylation reaction followed by a o...
|
|
WO/2002/022630A1 |
The present invention relates to compounds of formula (I) and phamaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of , and compositions containing such compoun...
|
|
WO/2002/020024A1 |
A method for treating arrhythmias is provided comprising administering a low dose of an adenosine receptor agonist, in particular CVT-510, to a mammal in need of such treatment.
|
|
WO/2002/020843A1 |
A method is provided for determining the sequence of a nucleic acid sequence via incubation of a primer extended product of the nucleic acid sequence in separate pools of semi-random oligonucleotides of 5'(N)¿n?A3', 5'(N)¿n?C3', 5'(N)Â...
|
|
WO/2002/020538A2 |
A process for the formation of Stavudine Polymorphic Form I from a mixture comprising Polymorphic Form I and at least one of Polymorphic Forms II and III is disclosed using the technique of Solution-Enhanced Dispersion by Supercritical F...
|
|
WO/2002/020842A1 |
The present invention provides a method and apparatus for to conduct transgenic and targeted mutagenesis screening of genomic DNA. This invention also provides a system for screening DNA for a designated genetic sequence. The system incl...
|
|
WO/2002/020150A2 |
Novel compounds are provided which are useful as linking groups in chemical synthesis, preferably in the solid phase synthesis of oligonucleotides and polypeptides. The compounds are generally photolabile and comprise protecting groups w...
|
|
WO/2002/020540A1 |
2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5'-monophosphate or salts thereof and drugs containing the same as the active ingredient. The above compounds have excellent effects of lowering ocular tension, promoti...
|
|
WO/2002/020537A2 |
A novel approach for combining the ease of cleavage of carboxylic acid linker arms with the single phosphoramidite coupling chemistry of the universal supports useful in oligonucleotide synthesis. There is disclosed a new class of phosph...
|
|
WO/2002/020539A1 |
2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5'-monophosphate or salts thereof and drugs containing the same as the active ingredient. The above-described compounds are excellent in the effect of lowering ocular t...
|
|
WO/2002/018388A1 |
Nucleoside analogs represented by the following general formula (1) and oligonucleotide derivatives containing one or more of the same wherein B represents an aromatic base having carbonyl oxygen at the 2-position or 2-hydroxyphenyl. The...
|
|
WO/2002/018406A1 |
The present invention is directed to nucleoside analogues with as substitute for the sugar part a 1,5-anhydrohexitol moiety, doexygenated and substituted with a nucleobase at the 2-position, of which the hexitorl ring is further substitu...
|
|
WO/2002/018371A1 |
The present invention provides a compound of formula (I), wherein: A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH¿2?, NHR?1¿, NR?1¿R?2¿ and SR?3¿, where R?1Â...
|
|
WO/2002/018405A2 |
The present invention provides methods for the chemical synthesis of nucleosides and derivatives thereof, including 2'-amino, 2'-N-phthaloyl, 2'-O-methyl, 2'-O-silyl, 2'-OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucle...
|
|
WO/2002/016382A1 |
A drug is modified by covalently coupling a blocking group to the drug via a nitrogen atom in the blocking group. The blocking group in the modified drug prevents metabolic conversion and sequestration of the drug in non-target cells, an...
|
|
WO/2002/014340A1 |
The present invention discloses methods for synthesizing oligomeric compounds. The methods include a modified phosphoramidite protocol wherein the oxidation and capping steps are combined into a single step. The methods result in increas...
|
|
WO/2002/012264A1 |
A process for producing a 2'-O-alkylguanosine from 2,6-diaminopurine riboside, characterized by using an aqueous medium to treat 2,6-diaminopurine riboside with an alkyl phosphate or alkyl sulfate as an alkylating agent under basic condi...
|
|
WO/2002/011668A2 |
Disclosed is a new fluorocytosine and derivatives thereof. The fluorocytosine and derivatives thereof provide a pharmaceutical composition exhibiting better anti-cancer characteristics than the conventional composition.
|
|
WO/2002/012261A1 |
Compounds of the general formula (I) or salts thereof, exhibiting antiparasitic activities wherein -X---Y- is -CH=CH- or the like; the symbol ---- between R?2¿ and the 5-position carbon atom is a single bond or a double bond; R?1¿ is l...
|
|
WO2001068663B1 |
Nucleoside analogs and their prodrug forms include a sugar moiety and a heterocyclic base moiety, wherein especially preferred sugar moieties include ribofuranose, and particularly preferred base moieties include diazole and triazole. Co...
|
|
WO/2002/012263A1 |
The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the dete...
|
|
WO/2002/010432A2 |
Hydrazino, oxyamino and carbonyl-based monomers and methods for incorporation into oligonucleotides during enzymatic synthesis are provided. Modified oligonucleotides are provided that incorporate the monomers provided herein. Immobilize...
|
|
WO/2002/009701A1 |
Angiogenesis is manipulated by administration of selective adenosine A¿1? allosteric enhancers can be administered in an amount effective to induce angiogenesis at a desired location for treating conditions in which increased angiogenes...
|
|
WO/2002/008241A2 |
A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of no...
|
|
WO/2002/004475A1 |
The present invention relates to 9-substituted adenine derivatives that inhibit adenylyl cyclase in cells but have little or no effect on isolated adenylyl cyclase. The derivatives are useful as prodrugs for inhibiting adenylyl cyclase a...
|
|
WO/2002/004474A1 |
An adenosine compound having the formula (I) wherein R represents a straight or branched lower alkyl group and R?1¿ represents a C¿2? to C¿6? lower alkylamino group or a substituent having the formula (II), (III) or (IV) wherein R?2¿...
|
|
WO/2002/003997A1 |
A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2', C3', C4' and/or C5' position. Particularly contemplated compounds also in...
|
|
WO/2002/002584A1 |
The present invention describes novel compounds of the formula (I) wherein Q is H or a sugar or a sugar analogue or a nucleic acid backbone or backbone analogue, Y=O, S, NR?10¿, where R?10¿ is H, alkyl alkenyl, alkynyl, X is H, alkyl, ...
|
|
WO/2002/000676A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compoun...
|
|
WO/2002/000200A1 |
The present invention relates to a novel process for preparing crystalline particles of a salt of a substance, particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy.
|
|
WO/2001/096356A1 |
Antisense molecules which act on both directions of the inhibition and restoration of the expression of a gene function and are capable of on/off switching appropriately depending on the external environment; and a method of reversibly c...
|
|
WO/2001/096353A2 |
The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compounds and compositions of 3'-esters of 2'-deoxy-$g(b)-L-nucleosides are disclosed, whic...
|
|
WO/2001/096355A1 |
Novel nucleoside derivatives represented by the following general formula (1) wherein Xs are the same or different and represent pyrimidine, purine nucleic acid base or derivative(s) thereof; Y and Y' are the same or different and repres...
|
|
WO/2001/096357A2 |
This invention pertains to solid-phase oligosynthesis, and more particularly to universal solid supports for solid-phase oligonucleotide synthesis, methods for their preparation, and methods for their use. One aspect of the invention per...
|
|
WO/2001/096609A1 |
A simple, nondestructive, and high throughput method for establishing DNA binding affinity and sequence selectivity is based on the loss of fluorescence derived from the displacement of ethidium bromide or thiazole orange from the DNA of...
|
|
WO/2001/096354A1 |
The invention concerns novel nucleotide analogues comprising a reactive hydrazide function used as initial synthons for preparing compounds (formula I) capable of inducing mutations or capable of inhibiting a DNA polymerase or a kinase. ...
|
